ClinicalTrials.gg
CompletedNCT00690066Updated Mar 11, 2026

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

A Phase 2 interventional study of PROCHYMAL® and Placebo in Type 1 Diabetes Mellitus, Type 1 Diabetes and Diabetes Mellitus, Insulin-Dependent, sponsored by Mesoblast, Inc.. Completed at 20 sites in United States. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Mesoblast, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2010, 15 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
454th of 1,242
63 · median 40
Started
2008
with 53 others
Phase 2
188 of 1,458
24 open now
Registered
215th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 454th largest by enrollment of the 1,242 interventional ones that give a count, is one of 54 that started in 2008, is one of 188 in phase 2, and was the 215th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.

Read the detailed description

Diabetes mellitus refers to disorders in which the body has trouble controlling its blood glucose levels. There are two main types of diabetes: type 1 and type 2. Type 1 diabetes mellitus (T1DM), which is being studied in this trial, is an autoimmune disorder in which the body's own immune system attacks and destroys the cells that make insulin. These cells are called beta cells. As beta cells are destroyed, less insulin can be made. This causes blood sugar levels to increase above normal and can cause life-threatening hypo- and hyper-glycemic reactions. For this reason, people with type 1 diabetes must take insulin to help control their blood sugar levels. Over time, poorly controlled diabetes can lead to a variety of serious health conditions, including heart disease, stroke, blindness, amputations, kidney disease, and nerve damage. Insulin is the primary method of controlling diabetes by regulating blood glucose levels, but it may not reverse or prevent disease progression. The active ingredient in PROCHYMAL® is adult human mesenchymal stem cells (MSCs). MSCs have been shown to interact with the immune cells in the body, reducing inflammation and assisting in tissue repair. This study will help determine whether MSCs can protect normal pancreatic tissue from autoimmune attack and repair damaged pancreatic tissue, leading to an increase in insulin production and decrease in circulating blood glucose. The characteristics and biologic activity of PROCHYMAL®, along with a good safety profile in human trials to date, suggest that PROCHYMAL® may be a good candidate for addressing Type 1 Diabetes.

03

Conditions studied

  • Type 1 Diabetes Mellitus
  • Type 1 Diabetes
  • Diabetes Mellitus, Insulin-Dependent
  • Juvenile Diabetes

Keywords

  • T1DM
  • Type 1 Diabetes Mellitus
  • Type 1 Diabetes
  • Diabetes Mellitus, Insulin-Dependent
  • Juvenile Diabetes
  • Adult Human Stem Cells
  • Mesenchymal Stem Cells
  • MSCs
  • Insulin
  • Osiris
  • Prochymal
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have a diagnosis of type 1 diabetes mellitus based on the American Diabetes Association (ADA) criteria.
  • Participant must be screened between 2 and 20 weeks from initial T1DM diagnosis
  • Participants must be between the ages of 12 and 35 (inclusive).
  • Participant must have at least one diabetes-related autoantibody present (either GAD or IA-2).
  • Participant must have some beta cell function as determined by C-peptide testing (at least 0.2 pmol/mL (0.6 ng/mL) during MMTT.
  • Participants must be willing to comply with "intensive diabetes management" as directed by the Investigator with the goal of maintaining blood glucose as close to normal as possible (i.e., glycosylated (HbA1c) value of ≤ 7.0%).
  • Participants must be willing to comply with the schedule of study visits and protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Participant has (BMI) ≥ 30.
  • Participant has evidence of retinopathy at baseline.
  • Participant has abnormally high lipid levels.
  • Participant has abnormal blood pressure.
  • Participant has an abnormal serum creatinine.
  • Participant has evidence of proteinuria.
  • Participant has diabetic ketoacidosis.
  • Participant is being treated for a severe active infection of any type.
  • A female participant who is breast-feeding, pregnant, or intends to become pregnant during the study.
  • Participant with clinically relevant uncontrolled medical condition not associated with diabetes (e.g. hematologic, renal, hepatic, neurologic, cardiac, or respiratory).
  • Participant has received an drug (not approved by the FDA) for any indication 30 days prior to the screening visit.
  • Participant is allergic to bovine or porcine products.
  • Participant has evidence of active or prior history of active malignancy that has not been in remission for at least 5 years.
  • Participant has any medical condition, which in the opinion of the Investigator, rendered his/her participation in this study unsuitable.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Prochymal

    PROCHYMAL®

    Drug: PROCHYMAL®

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells

    Also known as: ex vivo cultured adult human mesenchymal stem cells, Prochymal

  • DrugPlacebo

    Intravenous infusion of excipients of PROCHYMAL®

06

What researchers measure

Primary outcomes

  1. C-peptide area under the concentration curve (AUC) response (MMTT)

    Time frame: 1 year

Secondary outcomes

  1. Peak C-peptide response (MMTT)

    Time frame: 2 years

  2. Basal C-peptide response

    Time frame: 2 years

  3. Total daily insulin dose (units/kg)

    Time frame: 2 years

  4. Glycosylated hemoglobin (HbA1c) levels

    Time frame: 2 years

  5. Number of severe and documented hypoglycemic events

    Time frame: 2 years

  6. Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies

    Time frame: 2 years

07

Study locations

20 sites
  • University of Alabama, Division of Endocrinology & Metabolism
    Birmingham, Alabama 35294, United States
  • Scripps Whittier Diabetes Institute
    La Jolla, California 92037, United States
  • Stanford University
    Stanford, California 94305, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Diabetes Research Institute
    Miami, Florida 33136, United States
  • University of Kentucky
    Lexington, Kentucky 40502, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Desert Endocrinology CRC
    Henderson, Nevada 89052, United States
  • Nevada Alliance Against Diabetes
    Las Vegas, Nevada 89101, United States
  • University of North Carolina Diabetes Care Center
    Chapel Hill, North Carolina 27599, United States
  • American Health Research, Inc.
    Charlotte, North Carolina 28207, United States
  • The Lindner Clinical Trial Center
    Cincinnati, Ohio 45219, United States
  • Providence Health Partners - Center for Clinical Research
    Dayton, Ohio 45439, United States
  • Cumberland Valley Endocrinology
    Carlisle, Pennsylvania 17015, United States
  • AM Diabetes & Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Optimum Clinical Research, Inc.
    Salt Lake City, Utah 84102, United States
  • The Strelitz Diabetes Center, Eastern VA Medical School
    Norfolk, Virginia 23510, United States
  • University of Wisconsin Health- West Clinic
    Madison, Wisconsin 53717, United States
  • Clinical and Transitional Science Institute
    Milwaukee, Wisconsin 53226, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2008 to primary completion in Dec 2010, 30 months.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 30 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2008
First posted
Jun 4, 2008
StartActual
Jun 11, 2008
Primary completionActual
Dec 12, 2010
CompletionActual
Dec 19, 2011
Results delay requested
Dec 20, 2021
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00690066
Lead sponsor
Mesoblast, Inc.
Collaborators
Juvenile Diabetes Research Foundation
Responsible party
Sponsor
First posted
Jun 4, 2008
Start date
Jun 11, 2008
Primary completion
Dec 12, 2010
Completion
Dec 19, 2011
Last update
Mar 11, 2026

Study contacts

Mahboob Rahman, MD
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion